Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
Wei Zhang,1,2 Zhirong Li,3 Na Wang,1 Zhicong Yang,1 Jia Li,1 Caiqing Li,1 Xuying Han,1 Jinlu Liu,1 Liping Li,4 Shuwang Wang,4 Minghua Zhan1,5 1Microbiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, People’s Republic of China; 2Clinica...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/02784e7f95994b59ae042395cd98fb49 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:02784e7f95994b59ae042395cd98fb49 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:02784e7f95994b59ae042395cd98fb492021-11-14T19:00:30ZClinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/901178-6973https://doaj.org/article/02784e7f95994b59ae042395cd98fb492021-11-01T00:00:00Zhttps://www.dovepress.com/clinical-distribution-characteristics-of-1439-carbapenem-resistant-esc-peer-reviewed-fulltext-article-IDRhttps://doaj.org/toc/1178-6973Wei Zhang,1,2 Zhirong Li,3 Na Wang,1 Zhicong Yang,1 Jia Li,1 Caiqing Li,1 Xuying Han,1 Jinlu Liu,1 Liping Li,4 Shuwang Wang,4 Minghua Zhan1,5 1Microbiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, People’s Republic of China; 2Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China; 3Clinical Laboratory, Hebei Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 4Clinical Laboratory, Zhangjiakou Xuan Gang Hospital, Zhangjiakou, Hebei Province, People’s Republic of China; 5Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence: Minghua ZhanDepartment of Clinical Laboratory, The First Affiliated Hospital of Hebei North University and Peking University People’s Hospital, No. 11 South Street, Xi Zhi Men, Beijing, 100044, People’s Republic of ChinaTel +86-15531311750Fax +86-1088326317Email minghuazhan02@163.comPurpose: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread.Materials and Methods: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software.Results: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance.Conclusion: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest.Keywords: Enterobacteriales bacteria, multidrug resistance, MIC50/MIC90, regional distributionZhang WLi ZWang NYang ZLi JLi CHan XLiu JLi LWang SZhan MDove Medical Pressarticleenterobacterials bacteriamultidrug resistancemic50/mic90regional distributionInfectious and parasitic diseasesRC109-216ENInfection and Drug Resistance, Vol Volume 14, Pp 4717-4725 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
enterobacterials bacteria multidrug resistance mic50/mic90 regional distribution Infectious and parasitic diseases RC109-216 |
| spellingShingle |
enterobacterials bacteria multidrug resistance mic50/mic90 regional distribution Infectious and parasitic diseases RC109-216 Zhang W Li Z Wang N Yang Z Li J Li C Han X Liu J Li L Wang S Zhan M Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| description |
Wei Zhang,1,2 Zhirong Li,3 Na Wang,1 Zhicong Yang,1 Jia Li,1 Caiqing Li,1 Xuying Han,1 Jinlu Liu,1 Liping Li,4 Shuwang Wang,4 Minghua Zhan1,5 1Microbiology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, People’s Republic of China; 2Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China; 3Clinical Laboratory, Hebei Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 4Clinical Laboratory, Zhangjiakou Xuan Gang Hospital, Zhangjiakou, Hebei Province, People’s Republic of China; 5Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence: Minghua ZhanDepartment of Clinical Laboratory, The First Affiliated Hospital of Hebei North University and Peking University People’s Hospital, No. 11 South Street, Xi Zhi Men, Beijing, 100044, People’s Republic of ChinaTel +86-15531311750Fax +86-1088326317Email minghuazhan02@163.comPurpose: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread.Materials and Methods: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software.Results: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance.Conclusion: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest.Keywords: Enterobacteriales bacteria, multidrug resistance, MIC50/MIC90, regional distribution |
| format |
article |
| author |
Zhang W Li Z Wang N Yang Z Li J Li C Han X Liu J Li L Wang S Zhan M |
| author_facet |
Zhang W Li Z Wang N Yang Z Li J Li C Han X Liu J Li L Wang S Zhan M |
| author_sort |
Zhang W |
| title |
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| title_short |
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| title_full |
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| title_fullStr |
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| title_full_unstemmed |
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
| title_sort |
clinical distribution characteristics of 1439 carbapenem-resistant escherichia coli strains in china: drug resistance, geographical distribution, antibiotic mic50/90 |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/02784e7f95994b59ae042395cd98fb49 |
| work_keys_str_mv |
AT zhangw clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT liz clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT wangn clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT yangz clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT lij clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT lic clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT hanx clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT liuj clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT lil clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT wangs clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT zhanm clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 |
| _version_ |
1718428962142552064 |